China Ibrutinib Market Research Report 2018

March 2018 | 100 pages | ID: C58E4404494QEN
QYResearch

Abstracts

The global Ibrutinib market is valued at XX million USD in 2017 and is expected to reach XX million USD by the end of 2025, growing at a CAGR of XX% between 2017 and 2025.

China plays an important role in global market, with market size of xx million USD in 2017 and will be xx million USD in 2025, with a CAGR of xx%.

This report studies the Ibrutinib development status and future trend in China, focuses on top players in China, also splits Ibrutinib by type and by applications, to fully and deeply research and reveal the market general situation and future forecast.

The major players in China market include

• Pharmacyclics, Inc.
• Janssen Biotech, Inc.

Geographically, this report splits the China market into six regions,

• South China
• East China
• Southwest China
• Northeast China
• North China
• Central China
• Northwest China

On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into

• 140 mg
• 10 mg
• 5 mg

On the basis of the end users/application, this report covers

• Chronic Lymphocytic Leukaemia (CLL)
• Mantle Cell Lymphoma (MCL)
• Diffuse Large B Cell Lymphoma (DLBCL)
• Multiple Myeloma (MM)
• Follicular Lymphoma (FL)

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

China Ibrutinib Market Research Report 2018

1 IBRUTINIB OVERVIEW

1.1 Product Overview and Scope of Ibrutinib
1.2 Classification of Ibrutinib by Product Category
  1.2.1 China Ibrutinib Sales (K Units) Comparison by Type (2013-2025)
  1.2.2 China Ibrutinib Sales (K Units) Market Share by Type in 2017
  1.2.3 140 mg
  1.2.4 10 mg
  1.2.5 5 mg
1.3 China Ibrutinib Market by Application/End Users
  1.3.1 China Ibrutinib Sales (K Units) and Market Share Comparison by Applications (2013-2025)
  1.3.2 Chronic Lymphocytic Leukaemia (CLL)
  1.3.3 Mantle Cell Lymphoma (MCL)
  1.3.4 Diffuse Large B Cell Lymphoma (DLBCL)
  1.3.5 Multiple Myeloma (MM)
  1.3.6 Follicular Lymphoma (FL)
1.4 China Ibrutinib Market by Region
  1.4.1 China Ibrutinib Market Size (Million USD) Comparison by Region (2013-2025)
  1.4.2 South China Ibrutinib Status and Prospect (2013-2025)
  1.4.3 East China Ibrutinib Status and Prospect (2013-2025)
  1.4.4 Southwest China Ibrutinib Status and Prospect (2013-2025)
  1.4.5 Northeast China Ibrutinib Status and Prospect (2013-2025)
  1.4.6 North China Ibrutinib Status and Prospect (2013-2025)
  1.4.7 Central China Ibrutinib Status and Prospect (2013-2025)
1.5 China Market Size (Sales and Revenue) of Ibrutinib (2013-2025)
  1.5.1 China Ibrutinib Sales (K Units) and Growth Rate (%)(2013-2025)
  1.5.2 China Ibrutinib Revenue (Million USD) and Growth Rate (%)(2013-2025)

2 CHINA IBRUTINIB MARKET COMPETITION BY PLAYERS/MANUFACTURERS

2.1 China Ibrutinib Sales and Market Share of Key Players/Manufacturers (2013-2018)
2.2 China Ibrutinib Revenue and Share by Players/Manufacturers (2013-2018)
2.3 China Ibrutinib Average Price (USD/Unit) by Players/Manufacturers (2013-2018)
2.4 China Ibrutinib Market Competitive Situation and Trends
  2.4.1 China Ibrutinib Market Concentration Rate
  2.4.2 China Ibrutinib Market Share of Top 3 and Top 5 Players/Manufacturers
  2.4.3 Mergers & Acquisitions, Expansion in China Market
2.5 China Players/Manufacturers Ibrutinib Manufacturing Base Distribution, Sales Area, Product Types

3 CHINA IBRUTINIB SALES AND REVENUE BY REGION (2013-2018)

3.1 China Ibrutinib Sales (K Units) and Market Share by Region (2013-2018)
3.2 China Ibrutinib Revenue (Million USD) and Market Share by Region (2013-2018)
3.3 China Ibrutinib Price (USD/Unit) by Regions (2013-2018)

4 CHINA IBRUTINIB SALES AND REVENUE BY TYPE/ PRODUCT CATEGORY (2013-2018)

4.1 China Ibrutinib Sales (K Units) and Market Share by Type/ Product Category (2013-2018)
4.2 China Ibrutinib Revenue (Million USD) and Market Share by Type (2013-2018)
4.3 China Ibrutinib Price (USD/Unit) by Type (2013-2018)
4.4 China Ibrutinib Sales Growth Rate (%) by Type (2013-2018)

5 CHINA IBRUTINIB SALES BY APPLICATION (2013-2018)

5.1 China Ibrutinib Sales (K Units) and Market Share by Application (2013-2018)
5.2 China Ibrutinib Sales Growth Rate (%) by Application (2013-2018)
5.3 Market Drivers and Opportunities

6 CHINA IBRUTINIB PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 Pharmacyclics, Inc.
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Ibrutinib Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Pharmacyclics, Inc. Ibrutinib Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%)(2013-2018)
  6.1.4 Main Business/Business Overview
6.2 Janssen Biotech, Inc.
  6.2.1 Company Basic Information, Manufacturing Base and Competitors
  6.2.2 Ibrutinib Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Janssen Biotech, Inc. Ibrutinib Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%)(2013-2018)
  6.2.4 Main Business/Business Overview

7 IBRUTINIB MANUFACTURING COST ANALYSIS

7.1 Ibrutinib Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Ibrutinib

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Ibrutinib Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Ibrutinib Major Manufacturers in 2017
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 CHINA IBRUTINIB MARKET SIZE (SALES AND REVENUE) FORECAST (2018-2025)

11.1 China Ibrutinib Sales (K Units), Revenue (Million USD) Forecast (2018-2025)
11.2 China Ibrutinib Sales (K Units) Forecast by Type (2018-2025)
11.3 China Ibrutinib Sales (K Units) Forecast by Application (2018-2025)
11.4 China Ibrutinib Sales (K Units) Forecast by Region (2018-2025)

12 RESEARCH FINDINGS AND CONCLUSION

13 METHODOLOGY AND DATA SOURCE

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Global and China Market Size (Million USD) Comparison (2013-2025)
Table Ibrutinib Sales (K Units) and Revenue (Million USD) Market Split by Product Type
Table Ibrutinib Sales (K Units) by Application (2013-2025)
Figure Product Picture of Ibrutinib
Table China Ibrutinib Sales (K Units) and Growth Rate (%) Comparison by Types (Product Category) (2013-2025)
Figure China Ibrutinib Sales Volume Market Share by Types in 2017
Figure 140 mg Product Picture
Figure 10 mg Product Picture
Figure 5 mg Product Picture
Figure China Ibrutinib Sales (K Units) Comparison by Application (2013-2025)
Figure China Sales Market Share (%) of Ibrutinib by Application in 2017
Figure Chronic Lymphocytic Leukaemia (CLL) Examples
Table Key Downstream Customer in Chronic Lymphocytic Leukaemia (CLL)
Figure Mantle Cell Lymphoma (MCL) Examples
Table Key Downstream Customer in Mantle Cell Lymphoma (MCL)
Figure Diffuse Large B Cell Lymphoma (DLBCL) Examples
Table Key Downstream Customer in Diffuse Large B Cell Lymphoma (DLBCL)
Figure Multiple Myeloma (MM) Examples
Table Key Downstream Customer in Multiple Myeloma (MM)
Figure Follicular Lymphoma (FL) Examples
Table Key Downstream Customer in Follicular Lymphoma (FL)
Figure South China Ibrutinib Revenue (Million USD) and Growth Rate (2013-2025)
Figure East China Ibrutinib Revenue (Million USD) and Growth Rate (2013-2025)
Figure Southwest China Ibrutinib Revenue (Million USD) and Growth Rate (2013-2025)
Figure Northeast China Ibrutinib Revenue (Million USD) and Growth Rate (2013-2025)
Figure North China Ibrutinib Revenue (Million USD) and Growth Rate (2013-2025)
Figure Central China Ibrutinib Revenue (Million USD) and Growth Rate (2013-2025)
Figure China Ibrutinib Sales (K Units) and Growth Rate (%)(2013-2025)
Figure China Ibrutinib Revenue (Million USD) and Growth Rate (%)(2013-2025)
Table China Ibrutinib Sales of Key Players/Manufacturers (2013-2018)
Table China Ibrutinib Sales Share (%) by Players/Manufacturers (2013-2018)
Figure 2017 China Ibrutinib Sales Share (%) by Players/Manufacturers
Figure 2017 China Ibrutinib Sales Share (%) by Players/Manufacturers
Table China Ibrutinib Revenue by Players/Manufacturers (2013-2018)
Table China Ibrutinib Revenue Market Share (%) by Players/Manufacturers (2013-2018)
Figure 2017 China Ibrutinib Revenue Market Share (%) by Players/Manufacturers
Figure 2017 China Ibrutinib Revenue Market Share (%) by Players/Manufacturers
Table China Market Ibrutinib Average Price of Key Players/Manufacturers (2013-2018)
Figure China Market Ibrutinib Average Price of Key Players/Manufacturers in 2017
Figure China Ibrutinib Market Share of Top 3 Players/Manufacturers
Figure China Ibrutinib Market Share of Top 5 Players/Manufacturers
Table China Players/Manufacturers Ibrutinib Manufacturing Base Distribution and Sales Area
Table China Players/Manufacturers Ibrutinib Product Category
Table China Ibrutinib Sales (K Units) by Regions (2013-2018)
Table China Ibrutinib Sales Share (%) by Regions (2013-2018)
Figure China Ibrutinib Sales Share (%) by Regions (2013-2018)
Figure China Ibrutinib Sales Market Share (%) by Regions in 2017
Table China Ibrutinib Revenue (Million USD) and Market Share by Regions (2013-2018)
Table China Ibrutinib Revenue Market Share (%) by Regions (2013-2018)
Figure China Ibrutinib Revenue Market Share (%) by Regions (2013-2018)
Figure China Ibrutinib Revenue Market Share (%) by Regions in 2017
Table China Ibrutinib Price (USD/Unit) by Regions (2013-2018)
Table China Ibrutinib Sales (K Units) by Type (2013-2018)
Table China Ibrutinib Sales Share (%) by Type (2013-2018)
Figure China Ibrutinib Sales Share (%) by Type (2013-2018)
Figure China Ibrutinib Sales Market Share (%) by Type in 2017
Table China Ibrutinib Revenue (Million USD) and Market Share by Type (2013-2018)
Table China Ibrutinib Revenue Market Share (%) by Type (2013-2018)
Figure Revenue Market Share of Ibrutinib by Type (2013-2018)
Figure Revenue Market Share of Ibrutinib by Type in 2017
Table China Ibrutinib Price (USD/Unit) by Types (2013-2018)
Figure China Ibrutinib Sales Growth Rate (%) by Type (2013-2018)
Table China Ibrutinib Sales (K Units) by Applications (2013-2018)
Table China Ibrutinib Sales Market Share (%) by Applications (2013-2018)
Figure China Ibrutinib Sales Market Share (%) by Application (2013-2018)
Figure China Ibrutinib Sales Market Share (%) by Application in 2017
Table China Ibrutinib Sales Growth Rate (%) by Application (2013-2018)
Figure China Ibrutinib Sales Growth Rate (%) by Application (2013-2018)
Table Pharmacyclics, Inc. Ibrutinib Basic Information List
Table Pharmacyclics, Inc. Ibrutinib Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%)(2013-2018)
Figure Pharmacyclics, Inc. Ibrutinib Sales (K Units) and Growth Rate (%)(2013-2018)
Figure Pharmacyclics, Inc. Ibrutinib Sales Market Share (%) in China (2013-2018)
Figure Pharmacyclics, Inc. Ibrutinib Revenue Market Share (%) in China (2013-2018)
Table Janssen Biotech, Inc. Ibrutinib Basic Information List
Table Janssen Biotech, Inc. Ibrutinib Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%)(2013-2018)
Figure Janssen Biotech, Inc. Ibrutinib Sales (K Units) and Growth Rate (%)(2013-2018)
Figure Janssen Biotech, Inc. Ibrutinib Sales Market Share (%) in China (2013-2018)
Figure Janssen Biotech, Inc. Ibrutinib Revenue Market Share (%) in China (2013-2018)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Ibrutinib
Figure Manufacturing Process Analysis of Ibrutinib
Figure Ibrutinib Industrial Chain Analysis
Table Raw Materials Sources of Ibrutinib Major Players/Manufacturers in 2017
Table Major Buyers of Ibrutinib
Table Distributors/Traders List
Figure China Ibrutinib Sales (K Units) and Growth Rate (%) Forecast (2018-2025)
Figure China Ibrutinib Revenue (Million USD) and Growth Rate Forecast (2018-2025)
Figure China Ibrutinib Price (USD/Unit) Trend Forecast (2018-2025)
Table China Ibrutinib Sales (K Units) Forecast by Type (2018-2025)
Figure China Ibrutinib Sales (K Units) Forecast by Type (2018-2025)
Figure China Ibrutinib Sales Volume Market Share Forecast by Type in 2025
Table China Ibrutinib Sales (K Units) Forecast by Application (2018-2025)
Figure China Ibrutinib Sales Volume Market Share Forecast by Application (2018-2025)
Figure China Ibrutinib Sales Volume Market Share Forecast by Application in 2025
Table China Ibrutinib Sales (K Units) Forecast by Regions (2018-2025)
Table China Ibrutinib Sales Volume Share Forecast by Regions (2018-2025)
Figure China Ibrutinib Sales Volume Share Forecast by Regions (2018-2025)
Figure China Ibrutinib Sales Volume Share Forecast by Regions in 2025
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources